| Sean Caskey, DO | |
|
520 N Chelan Ave, Wenatchee, WA 98801-6697 | |
| (509) 662-8756 | |
| Not Available |
| Full Name | Sean Caskey |
|---|---|
| Gender | Male |
| Speciality | Orthopaedic Surgery |
| Location | 520 N Chelan Ave, Wenatchee, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063861102 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207XS0114X | Orthopaedic Surgery - Adult Reconstructive Orthopaedic Surgery | OP61282583 (Washington) | Secondary |
| 207X00000X | Orthopaedic Surgery | OP61282583 (Washington) | Primary |
| Entity Name | Central Washington Health Services Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801937453 PECOS PAC ID: 4880504596 Enrollment ID: O20031106000287 |
News Archive
The number of acute coronary events such as heart attack in adults dropped significantly after a smoking ban in public places in Italy, researchers reported in Circulation: Journal of the American Heart Association.
Patients undergoing treatment for melanoma that has spread to the liver may respond well to chemotherapy delivered directly into the liver's blood vessels, according to a study sponsored by the National Cancer Institute and Delcath Systems Inc., and led by James F. Pingpank, M.D., associate professor of surgery, University of Pittsburgh School of Medicine, and surgical oncologist with UPMC Cancer Centers. The results will be disclosed in an oral presentation on June 5 in Chicago at the 46th annual meeting of the American Society of Clinical Oncology (ASCO).
Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.
Researchers at The Ontario Institute for Cancer Research and University Health Network, have identified a new DNA-based test that could be used to better predict how prostate cancer patients will respond to treatment and to prevent relapse.
Cardiology researchers at the Intermountain Medical Center Heart Institute have found that approximately 75 percent of patients taking two common blood-thinning drugs may be receiving the wrong dosage levels, according to a new study.
› Verified 4 days ago
| Entity Name | Wenatchee Valley Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669719688 PECOS PAC ID: 9537309869 Enrollment ID: O20130716000034 |
News Archive
The number of acute coronary events such as heart attack in adults dropped significantly after a smoking ban in public places in Italy, researchers reported in Circulation: Journal of the American Heart Association.
Patients undergoing treatment for melanoma that has spread to the liver may respond well to chemotherapy delivered directly into the liver's blood vessels, according to a study sponsored by the National Cancer Institute and Delcath Systems Inc., and led by James F. Pingpank, M.D., associate professor of surgery, University of Pittsburgh School of Medicine, and surgical oncologist with UPMC Cancer Centers. The results will be disclosed in an oral presentation on June 5 in Chicago at the 46th annual meeting of the American Society of Clinical Oncology (ASCO).
Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.
Researchers at The Ontario Institute for Cancer Research and University Health Network, have identified a new DNA-based test that could be used to better predict how prostate cancer patients will respond to treatment and to prevent relapse.
Cardiology researchers at the Intermountain Medical Center Heart Institute have found that approximately 75 percent of patients taking two common blood-thinning drugs may be receiving the wrong dosage levels, according to a new study.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sean Caskey, DO 820 N Chelan Ave, Wenatchee, WA 98801-2028 Ph: (509) 663-8711 | Sean Caskey, DO 520 N Chelan Ave, Wenatchee, WA 98801-6697 Ph: (509) 662-8756 |
News Archive
The number of acute coronary events such as heart attack in adults dropped significantly after a smoking ban in public places in Italy, researchers reported in Circulation: Journal of the American Heart Association.
Patients undergoing treatment for melanoma that has spread to the liver may respond well to chemotherapy delivered directly into the liver's blood vessels, according to a study sponsored by the National Cancer Institute and Delcath Systems Inc., and led by James F. Pingpank, M.D., associate professor of surgery, University of Pittsburgh School of Medicine, and surgical oncologist with UPMC Cancer Centers. The results will be disclosed in an oral presentation on June 5 in Chicago at the 46th annual meeting of the American Society of Clinical Oncology (ASCO).
Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.
Researchers at The Ontario Institute for Cancer Research and University Health Network, have identified a new DNA-based test that could be used to better predict how prostate cancer patients will respond to treatment and to prevent relapse.
Cardiology researchers at the Intermountain Medical Center Heart Institute have found that approximately 75 percent of patients taking two common blood-thinning drugs may be receiving the wrong dosage levels, according to a new study.
› Verified 4 days ago
Jeffrey Allan Pratt, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 520 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-662-2211 Fax: 509-662-8756 | |
Dr. Mark A. Broberg, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 520 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-662-2211 Fax: 509-662-8756 | |
Eric Thorson, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Dr. Roger J Starkweather, MD Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 304 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-662-3838 Fax: 509-663-1108 | |
Dr. Keary P. Kunz, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 520 N Chelan Ave, Wenatchee Orthopaedics, Wenatchee, WA 98801 Phone: 509-662-2211 Fax: 509-662-8756 | |
Benjamin Albertson, MD Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 |